Invion Limited

Positive Result for Photosoft^TMin Ovarian Cancer Treatment:Australian life-sciences company, Invion Limited (ASX: IVX) focuses on transforming Photodynamic Therapy (PDT) for novel and effective treatments for cancer.Recently, the company announced the results from a pre-clinical study undertaken by Hudson Institute of Medical Research over mice with ovarian cancer. Photosoft^TM caused the immediate and specific death of tumour tissue, with no apparent adverse effects in the surrounding healthy tissues. The size of the tumours in animals treated with Photosoft^TM Technology reduced to less than half of their original size over a three-week period. Tumour destruction was accompanied by an influx of immune cells, indicating an anti-tumour immune response. The outcome is significant for cancer treatment as traditional chemotherapy can kill healthy cells and suppress the body’s natural ability to fight infections.

As per the release, there are 1,500 new cases of ovarian cancer in Australia every year, with around 4,000 to 5,000 Australians currently living with the disease. Internationally, there are around 240,000 new cases a year. Half of those diagnosed with cancer will succumb to the disease within five years of the diagnosis. The company is developing an optimised version of Photosoft^TM called IVX-PDT, which is better suited to large-scale GMP manufacturing while meeting clinical and regulatory requirements. Moving forward, IVX will be starting Phase 1b human trials of IVX-PDT to treat skin cancer, while Peter MacCallum Cancer Institute will be commencing studies using IVX-PDT for the treatment of ano-genital cancer in 2020.


September’19 Quarter Operating Cash Flow (Source: Company Reports)

September’19 Quarter Key Highlights:Net cash outflow from operating activities for the quarter was reported at $205,000. Cash and cash equivalents at the end of the quarter were reported at $558,000.

Stock Recommendation:IVX’s share generated a negative YTD return of 55.56%, and currently, the stock is trading below the average of 52-week high and low levels of $0.029 and $0.008, respectively. Its cash cycle for FY19 stood at 10 days, better than the industry median of 138.3 days. However, it is yet to show positive profitability margins. Company’s positive results for its product to treat ovarian cancers are expected to be a revolution in the cancer treatment process and may replace the existing complex chemotherapy method.Hence, considering the aforesaid facts and current trading levels, we suggest investors to adopt a wait and watch stance on the stock at the current market price of $0.017, up 112.5% on November 27, 2019, taking cues from the recently released results of the pre-clinical study.
 

Prescient Therapeutics Limited

PTX’s Share Surged ~33% Over Third Complete Response in PTX-200 Trial:Prescient Therapeutics Limited (ASX: PTX) is involved in preparation for and conduct of clinical trials relating to the company’s drug; business development associated with the promotion of Prescient’s proprietary technologies and products; and business development associated with developing collaborative, partnership relationships and corporate transactions. On November 27, 2019, the company announced that it would expand its Phase 1b study in patients with acute myeloid leukemia (AML), following an encouraging third complete response. Three, out of 15 patients experienced complete responses in the study in relapsed or refractory AML patients, which is difficult to treat cancer population. The three complete responses observed are very encouraging in a hard to treat the patient population. The company aims to get more patients through more cycles of therapy following the protocol amendment.

September’19 Quarter Key Highlights:Net cash outflow from operating activities for the period was reported at $0.95 Mn. Cash reserves at the end of the period were reported at $8.71 Mn. The company opened the first clinical trial of its novel targeted therapy, PTX-100. The Phase 1b PTX-100 ‘basket’ study is designed to determine the optimal dose and treatment schedule of PTX-100 in myeloma, T-cell lymphomas, gastric and pancreatic cancers with Ras and RhoA mutations.


September’19 Quarter Operating Cash Flow (Source: Company Reports)

Stock Recommendation:PTX’s share generated a positive YTD return of 13.98%. Company’s PTX-100 trial is underway and is uniquely positioned in hot Ras space. Both the drugs PTX-100 and PTX-200 have potential advantages over competitors’ approaches. Moreover, a capital raising worth $9 Mn supported by existing shareholders and several leading US and Australian specialist life science investors, is expected to help the company in meeting its future growth plans, and in turn, delivering better value to shareholders. The stock as on November 27, 2019 surged ~33% on the third complete response in PTX-200 AML trial. Hence, considering the aforesaid facts and current trading levels, we have a wait and watch stance on the stock at the current market price of $0.100, up 33.333% on November 27, 2019.

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.